Since altered iron metabolism is known to occur in advanced liver disease and patients with hemochromatosis are at risk for liver disease, the effect of HFE mutations was explored in a group of 380 Pi*ZZ carriers (246 C282Y/H63D non‐carriers, 24 C282Y heterozygous carriers, 99 H63D heterozygous carriers, 7 H63D homozygous carriers, 4 C282Y/H63D compound heterozygous carriers). Here, HFE is linked to liver disorder.